secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001193125-25-317784
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO
----------------------------------------------------------------------------

- CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.
- COO Jennifer Bush surrendered 84,877 options (60,372 vested, 24,506 unvested) for equivalent RSUs.
- RSUs vest between Aug 2026 and Feb 2029; acceleration on termination without cause or resignation for good reason.
- Purpose: retain employees and align interests with stockholders by replacing underwater options with current-value equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/0001193125-25-317784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/artv-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-317784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer